NASDAQ: PLSEPulse Biosciences Inc Stock
$44.54-0.38 (-0.85%)
Updated Aug 14, 2026
PLSE Price
$44.54
Fair Value Price
$1.08
Market Cap
$3.18B
52 Week Low
$12.56
52 Week High
$46.91
P/E
-37.75x
P/B
31.93x
P/S
1,619.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.19M
Earnings
-$80.06M
Gross Margin
0.3%
Operating Margin
-6,755.78%
Profit Margin
-6,755.8%
Debt to Equity
0.16
Operating Cash Flow
-$61M
Beta
1.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PLSE Overview
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PLSE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
PLSE
Ranked#36 of 39
Ranked#36 of 39
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $90.80 | A | |
| $182.98 | A | |
| $12.27 | A |
Be the first to know about important PLSE news, forecast changes, insider trades & much more!
PLSE News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PLSE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PLSE ($44.54) is overvalued by 4,019.8% relative to our estimate of its Fair Value price of $1.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PLSE ($44.54) is not significantly undervalued (4,019.8%) relative to our estimate of its Fair Value price of $1.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PLSE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PLSE due diligence checks available for Premium users.
Valuation
PLSE fair value
Fair Value of PLSE stock based on Discounted Cash Flow (DCF)
Price
$44.54
Fair Value
$1.08
Overvalued by
4,019.80%
PLSE ($44.54) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PLSE ($44.54) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PLSE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PLSE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-37.75x
Industry
44.08x
Market
15.95x
PLSE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
31.93x
Industry
3.37x
PLSE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PLSE's financial health
Profit margin
Revenue
$434.0k
Net Income
-$24.7M
Profit Margin
-5,681.3%
PLSE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PLSE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$115.6M
Liabilities
$16.1M
Debt to equity
0.16
PLSE's short-term assets ($105.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLSE's short-term assets ($105.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLSE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PLSE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.7M
Investing
-$90.0k
Financing
$52.1M
PLSE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PLSE vs Medical Stocks
Pulse Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.